ML-SYS / 2026.07NON-CLINICAL RESEARCH MATERIALSORIGIN DECLARED BY LOT

← Compound index

RM-END / Endocrine and peptide-hormone analogs

Cetrorelix

Also known as: Cetrotide · Cetrorelix acetate · SB-75

Approved comparator exists

Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.

What this is

Cetrorelix is a synthetic decapeptide antagonist of GnRH. Exact substitutions distinguish it from ganirelix, degarelix and GnRH agonists.

Evidence position

The regulated injection kit and human evidence support Grade A for the named finished product.

What the record does not establish

The label does not authenticate a separate research sample or make different presentations equivalent.

Sources

  • 01
    Cetrorelix compound recordPubChem
    Shows
    Registry identity, structure, formula and synonyms for cetrorelix
    Does not show
    Does not establish a kit formulation, approval transfer or lot quality
  • 02
    Cetrotide prescribing informationDailyMed / U.S. National Library of Medicine
    Shows
    Current U.S. label, decapeptide identity and regulated injection presentation
    Does not show
    Does not qualify a different salt, concentration, kit or source

External database index

LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE

Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.

PUBMED / FOUND RECORDS

  1. Efficacy of GnRH antagonists in the treatment of uterine fibroids: a meta-analysis.Archives of gynecology and obstetrics / 2025 MarPMID 39821450 / DOI 10.1007/s00404-025-07932-9
  2. LHRH antagonists.Pharmaceutical biotechnology / 1998PMID 9760679 / DOI 10.1007/0-306-47384-4_7
  3. What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis.Human reproduction update / 2023 May 2PMID 36594696 / DOI 10.1093/humupd/dmac040
  4. Arzneimittelentwicklung in der Onkologie. Status und Ausblick unter besonderer Berucksichtigung des Standortes Deutschland.Arzneimittel-Forschung / 2000 OctPMID 11105239 / DOI 10.1055/s-0031-1300308
  5. Cetrorelix in reproductive medicine.F&S reports / 2023 JunPMID 37223762 / DOI 10.1016/j.xfre.2022.11.012

CLINICALTRIALS.GOV / FOUND RECORDS

  1. Coasting Versus Antagonist Protocol in Patients at High Risk of OHSSCOMPLETED / PHASE4 / ClinAmygateNCT03996434 / DIRECT intervention MATCH: Cetrorelix
  2. Progesterone-Primed Ovarian Simulation in Controlled-ovarian Simulation of Infertile PCOS PatientsCOMPLETED / NA / Zagazig UniversityNCT05939284 / DIRECT intervention MATCH: Cetrorelix
  3. Gonadotropin-releasing Hormone Antagonist on Triggering Day: A Randomized Controlled StudyCOMPLETED / NA / Seoul National University Bundang HospitalNCT00571870 / DIRECT intervention MATCH: Cetrorelix
  4. Cetrotide Treatment OptimizationTERMINATED / PHASE4 / Bart CJM FauserNCT00866034 / DIRECT intervention MATCH: Cetrorelix
  5. Study on Influence of Leutinizing Hormone (LH) on Oocyte MaturityUNKNOWN / NA / Southern Cross Fertility CentreNCT01595334 / DIRECT intervention MATCH: Cetrorelix

Related compounds

RM-END

Ganirelix

Read entry →
RM-END

Degarelix

Read entry →
RM-END

Gonadorelin

Read entry →